Valuation : Structure Therapeutics Inc.

Market Cap 3.38B 2.9B 2.73B 2.5B 4.67B 319B 4.68B 32.3B 12.53B 164B 12.68B 12.4B 527B P/E 2026 *
-29.2x
P/E 2027 * -21.6x
Enterprise Value 2.41B 2.07B 1.95B 1.78B 3.33B 227B 3.34B 23.04B 8.94B 117B 9.04B 8.85B 376B EV / Sales 2026 *
62.6x
EV / Sales 2027 * 67,593x
Free-Float
94.05%
Yield 2026 *
-
Yield 2027 * -
1 week-0.06%
Current month+3.11%
1 month-4.63%
3 months+21.20%
6 months-25.01%
Current year-31.93%
1 week 45.1
Extreme 45.1
48.64
1 month 45.1
Extreme 45.1
55.6
Current year 35.78
Extreme 35.78
94.77
1 year 20.04
Extreme 20.04
94.9
3 years 13.22
Extreme 13.22
94.9
5 years 13.22
Extreme 13.22
94.9
10 years 13.22
Extreme 13.22
94.9
Manager TitleAgeSince
Director of Finance/CFO 48 01/05/2022
Chief Executive Officer 62 01/05/2019
Chief Operating Officer 49 15/04/2026
Director TitleAgeSince
Director/Board Member 62 01/02/2019
Chairman 68 19/01/2022
Director/Board Member 66 29/03/2022
Date Insider Type Main position Quantity % Market Cap. Importance
1/9/26 Exercice

Chief Technology Officer

65,329 0.0467%
18/8/26 Exercice

Chief Technology Officer

43,329 0.0310%
4/8/26 Exercice

Chief Technology Officer

43,329 0.0310%
Change 5-day change 1-year change 3-year change Capi.($)
0.00%-0.06% - - 3.38B
Average 0.00%
Weighted average by Cap. 0.00%

Financials

2026 *2027 *
Net sales 38.46M 33.1M 31.14M 28.45M 53.21M 3.63B 53.36M 368M 143M 1.86B 144M 141M 6B 41.67K 35.86K 33.74K 30.82K 57.65K 3.93M 57.81K 399K 155K 2.02M 156K 153K 6.5M
Net income -309M -265M -250M -228M -427M -29.13B -428M -2.95B -1.15B -14.95B -1.16B -1.13B -48.15B -475M -409M -385M -352M -658M -44.88B -659M -4.55B -1.76B -23.03B -1.79B -1.75B -74.18B
Net Debt -967M -832M -783M -715M -1.34B -91.31B -1.34B -9.25B -3.59B -46.85B -3.63B -3.55B -151B -559M -481M -453M -414M -774M -52.8B -776M -5.35B -2.08B -27.09B -2.1B -2.05B -87.27B
Logo Structure Therapeutics Inc.
Structure Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing oral small molecule treatments for chronic metabolic and cardiopulmonary conditions with significant unmet medical needs. Its programs include Aleniglipron (GSBR-1290), ACCG-2671, GIP and GCG Receptor Oral Small Molecule Obesity Programs, ANPA-0073, and LTSE-2578. Its Aleniglipron is an oral and biased small molecule agonist of GLP-1R, a validated GPCR drug target for obesity. ACCG-2671 is an oral small molecule amylin receptor agonist for obesity. ANPA-0073 is a biased agonist targeting the apelin (APJ) receptor agonist. Its LTSE-2578, an Oral Small Molecule LPA1R Antagonist for IPF. It is developing an antagonist that targets lysophosphatidic acid 1 receptor (LPA1R), a GPCR implicated in responses to tissue injury and pro-fibrotic processes, for the treatment of IPF. It is developing oral incretins for potential combination therapy with GLP-1R or amylin candidates.
Employees
281
Date Price Change Volume
04/09/26 USD 47.34 0.00% 281,709
03/09/26 USD 47.34 -0.96% 621,486
02/09/26 USD 47.80 +1.42% 1,064,737
01/09/26 USD 47.13 +2.66% 816,626
31/08/26 USD 45.91 -3.08% 1,394,959
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
16
Last Close Price
47.34USD
Average target price
104.77USD
Spread / Average Target
+121.31%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. GPCR Stock